UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 17, 2018 (October 11, 2018)

 

 

 

Heyu Biological Technology Corporation

(Exact Name of Registrant as Specified in its Charter)

  

 

 

Nevada

 

000-26731 

 

 

87-0627910 

(State or Other Jurisdiction of
Incorporation)

 

 

(Commission
 File Number)

 

 

(IRS Employer
Identification Number)

   

4th Floor, No. 10 Building, Xinglin Bay Business Operation Center,

Jimei District, Xiamen City,

Fujian Province, China 361022

(Address of Principal Executive Offices, Zip Code)

 

Registrant’s telephone number, including area code: (86) 158 5924 0902

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

Item 8.01 Other Events. 

 

As of October 11, 2018, Heyu Biological Technology Corporation (the “Company”) is currently nearing the completion of an on-site due diligence investigation of both the financial and legal aspects of Fujian Shanzhiling Biological Technology Co., Ltd (the “Acquirer”). The due diligence investigation is done pursuant to the non-binding letter of intent entered into between the Company and the Acquirer on October 8, 2018, whereby the Acquirer has agreed to acquire 51 percent (51%) of the outstanding capital of the Company subject to certain adjustment provisions (the “Acquisition”). The Company and the Acquirer are in the final phase of negotiations and are working to close the Acquisition as soon as possible.

As of the date of this current report, there is no definitive agreement entered into between the Company and the Acquirer and there is no assurance the aforementioned transaction will be consummated.

 

 1 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

   

Heyu Biological Technology Corporation
   
  By:  /s/ Ban Siong Ang
 

Name:

Title:

Ban Siong Ang
Chief Executive Officer
     
  Dated: October 17, 2018

 

 2